Irati
Garmendia Iturbe
Investigadora hasta 2019
Publicaciones en las que colabora con Miriam Redrado Jordán (3)
2022
-
YES1 Is a Druggable Oncogenic Target in SCLC
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403
2021
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
2014
-
New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations
International Journal of Cancer, Vol. 135, Núm. 11, pp. 2516-2527